Create Free Account

By creating account you will get access to hot stocks & personalised emails

Syntara Limited

Healthcare AU SNT

0.064AUD
0.002(3.23%)

Last update at 2024-12-19T05:11:00Z

Day Range

0.060.06
LowHigh

52 Week Range

0.010.07
LowHigh

Fundamentals

  • Previous Close 0.06
  • Market Cap87.88M
  • Volume9864983
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-13.49400M
  • Revenue TTM5.76M
  • Revenue Per Share TTM0.006
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.01

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown
Breakdown
Breakdown

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SNT
Syntara Limited		 0.002 3.23% 0.06 - 20.45 15.25 19.66 6.32 -2.1607
AFP
AFT Pharmaceuticals Ltd		 -0.04 1.54% 2.55 25.90 19.08 1.39 3.57 1.61 13.92
LV1
Live Verdure Ltd		 0.02 2.56% 0.80 - - 68.21 49.49 66.86 -5.083
VLS
Vita Life Sciences Ltd		 - -% 1.78 11.12 - 1.34 2.16 0.99 5.71
PER
Percheron Therapeutics Limited		 - -% 0.007 - - 23.08 8.13 347.00 -4.4641

Reports Covered

Stock Research & News

View All

Profile

Syntara Limited operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. The company's lead product candidate is SNT-5505, which is in Phase 2 trial to treat myelofibrosis, myelodysplastic syndrome, hepatocellular carcinoma, and pancreatic cancer, as well as scar prevention. It also develops SNT-4728 in Phase 2 trial for the treatment of neurodegenerative diseases comprising isolated rapid eye movement sleep behavior disorder (IRBD) and Parkinson's disease; SNT-5382, which is a selective lysyl oxidase-like 2 inhibitor in Phase 1 trial to treat chronic fibrosis; and SNT-8370 for the treatment of inflammation. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Syntara Limited

20A Rodborough Road, Frenchs Forest, NSW, Australia, 2086

Key Executives

Name Title Year Born
Mr. Gary Jonathan Phillips BPharm, MBA CEO, MD & Director 1961
Mr. David Morris McGarvey BA, CA, CPA CFO & Company Secretary 1956
Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D. Head of Drug Discovery 1964
Ms. Kristen Morgan B.Sc., BSc, MMedSc, PGDipBusAdmin Head of Medical & Regulatory Affairs - Alliance Management 1972
Mr. Gary Jonathan Phillips BPharm, MBA CEO, MD & Director 1961
Mr. David Morris McGarvey BA, CA, CPA CFO & Company Secretary 1956
Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D. Head of Drug Discovery 1964
Mr. Gary Jonathan Phillips BPharm, MBA CEO, MD & Director 1961
Mr. David Morris McGarvey BA, CA, CPA CFO & Company Secretary 1956
Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D. Head of Drug Discovery 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.